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Abstract  1 
The case-control methodology is frequently used to evaluate vaccine effectiveness post-licensure. The 2 
results of such studies provide important insight into the level of protection afforded by vaccines in a 3 
‘real world’ context, and are commonly used to guide vaccine policy decisions. However, the potential 4 
for bias and confounding are important limitations to this method, and the results of a poorly conducted 5 
or incorrectly interpreted case-control study can mislead policies. In 2012, a group of experts met to 6 
review recent experience with case-control studies evaluating vaccine effectiveness; we summarize the 7 
recommendations of that group regarding best practices for data collection, analysis, and presentation 8 
of the results of case-control vaccine effectiveness studies. Vaccination status is the primary exposure of 9 
interest, but can be challenging to assess accurately and with minimal bias. Investigators should 10 
understand factors associated with vaccination as well as the availability of documented vaccination 11 
status in the study context; case-control studies may not be a valid method for evaluating vaccine 12 
effectiveness in settings where many children lack a documented immunization history. To avoid bias, it 13 
is essential to use the same methods and effort gathering vaccination data from cases and controls. 14 
Variables that may confound the association between illness and vaccination are also important to 15 
capture as completely as possible, and where relevant, adjust for in the analysis according to the 16 
analytic plan. In presenting results from case-control vaccine effectiveness studies, investigators should 17 
describe enrollment among eligible cases and controls as well as the proportion with no documented 18 
vaccine history. Emphasis should be placed on confidence intervals, rather than point estimates, of 19 
vaccine effectiveness. Case-control studies are a useful approach for evaluating vaccine effectiveness; 20 
however careful attention must be paid to the collection, analysis and presentation of the data in order 21 
to best inform evidence-based vaccine policies.   22 
Key words: vaccines, case-control studies, evaluation studies   23 
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Introduction  24 
New vaccines are licensed based on the results of randomized controlled trials demonstrating 25 
safety and efficacy. Yet even after licensure, there are often questions about how well a vaccine protects 26 
against disease in a “real world” context because of differences in epidemiologic contexts, host factors 27 
affecting immune response, vaccine implementation (e.g. varying dosing schedules), and the potential 28 
for waning immunity over time1 The case-control method is commonly used to estimate effectiveness 29 
after a vaccine has been implemented in a public health system; recent examples include evaluations of 30 
vaccines against  Haemophilus Influenzae type B (Hib)2-13, Streptococcus pneumoniae 14-21, influenza22, 31 
rotavirus23-36, and cholera37-39. The results of case-control vaccine effectiveness studies can complement 32 
and extend the data generated by clinical trials.  33 
However the potential for bias and confounding are important limitations to the case-control 34 
method40,41. In 2012, a group of experts met to review recent experience with case-control studies 35 
evaluating the effectiveness of several vaccines; here we summarize the recommendations of that group 36 
regarding best practices for data collection, analysis and interpretation. (A separate paper provides an 37 
overview of the case-control method for evaluating vaccine effectiveness and reviews planning, design, 38 
and the identification and enrollment of cases and controls.) While case-control vaccine effectiveness 39 
studies have been carried out in countries of all income levels, this review focuses on their 40 
implementation in resource-poor settings.  41 
Assessment of vaccination status 42 
 Vaccination status is the primary exposure of interest for case-control vaccine effectiveness 43 
studies, but it can be challenging to assess it accurately42. Misclassification of vaccination status can 44 
affect the VE estimates in various ways. Non-differential misclassification of vaccination status (i.e. cases 45 
and controls have similar risks of misclassification) will bias the effectiveness estimate towards the 46 
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null41. Differential misclassification (i.e. vaccine classification errors have different probabilities in cases 47 
and controls) can bias the effectiveness estimate towards or away from the null, or even result in a 48 
negative VE, giving the false impression that vaccinated are at greater risk of the target disease than 49 
unvaccinated41. The same strategies to obtain vaccination history should be used for both cases and 50 
controls. Equal, intense effort must be made to obtain vaccination histories from all cases and 51 
controls40,43, and those efforts should be clearly documented and reported. 52 
Preferred sources of vaccination data are family-held vaccine records, clinic records, 53 
immunization registry data, or other written documentation of vaccines received and the dates on 54 
which they were administered. Doses not recorded on these documents are assumed to have not been 55 
received; although this assumption may be incorrect if recordkeeping is poor.  Parent reporting of 56 
routine infant immunizations received, without written verification, may be unreliable44. However, if 57 
parents report receipt of no vaccines of any type or receipt of only birth doses, such a history may be 58 
valid even in the absence of written confirmation since unvaccinated children rarely will have family-59 
held records and generally parents are unlikely to state that the child is unvaccinated when in fact he or 60 
she did receive vaccines. Because excluding unvaccinated children will lead to bias, children with a 61 
parental report of having received no routine vaccines beyond birth doses should be included and 62 
considered to have received no doses of the vaccine of interest.  All eligible cases and controls should be 63 
enrolled regardless of whether a documented vaccination history is available at the time of enrollment. 64 
Although those lacking a confirmed vaccination history (other than unvaccinated children) will be 65 
excluded from primary analyses because of missing data, the proportion of enrolled children for whom 66 
vaccination history could not be obtained should be described in the results, and sensitivity analyses 67 
used to assess the impact of missing data on the effectiveness estimates (see Analysis section).  68 
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 Investigators should endeavor to understand factors associated with vaccination card 69 
availability and retention in the study setting, and whether those factors may also be linked to risk of 70 
disease or likelihood of vaccination45. In preparation for the study, efforts can be made to improve 71 
availability of cards and/or the quality and completeness of data in the clinic records. If vaccine histories 72 
are unavailable for a sizeable proportion of children in the area (e.g. ≥5-10%), then efforts should be 73 
made to assess differences between children with and without documented histories. If important 74 
differences exist with regards with risk factors for disease, then a case-control study in that context is 75 
likely to yield biased effectiveness estimates. Case-control studies may not be a valid method for 76 
evaluating VE in settings where more than a small fraction of children lack a documented immunization 77 
history.   78 
Abstracting vaccination data from family-held cards or clinic records is not always 79 
straightforward and can be a source of bias. Copies of the vaccination data source (e.g. digital photo, 80 
photocopies, or scanned images of the card or record) are extremely useful for controlling data quality. 81 
Copies can be used for double-abstraction (e.g. by two independent observers), which may improve the 82 
quality of data, particularly in settings where interpretation of information in the record may be 83 
challenging, for example, where parental-held records have no dedicated space for a new vaccine or for 84 
vaccines administered during campaigns. Copies potentially allow for blinding with regard to case or 85 
control status for the person abstracting the vaccination data40. Vaccine lot numbers, if recorded, can 86 
aid in determining which vaccines were received. Dates of all relevant vaccine doses, including the 87 
vaccine of interest and other vaccines given on the same or similar schedules, should be carefully 88 
recorded.  89 
Other variables and unmeasured confounding factors 90 
6 
 
In addition to vaccination status, data should be gathered on other variables that may confound 91 
the association between vaccination and the disease of interest46,47.  Known or hypothesized 92 
confounders should be identified before study initiation, accurately and thoroughly captured during 93 
data collection, and adjusted for in the analysis if they confound the association between vaccination 94 
and illness. As with all observational studies, some degree of unmeasured confounding often occurs in 95 
case-control studies and has the potential to substantially alter the measured VE48. Unmeasured 96 
confounding may result from failure to collect data on a known confounder, insufficient or inadequate 97 
data collection for a known confounder, or lack of data on an unrecognized or unknown confounder.  98 
A few strategies to quantify unmeasured confounders have been suggested. The first has been 99 
called a “bias-indicator” 37,39,49 or “sham outcome”50 study. This is performed concurrently with a case-100 
control study of vaccine effectiveness, where the effectiveness of the studied vaccine is measured 101 
against another disease which is not expected to be prevented by the vaccine37,39,49.   As the vaccine 102 
should confer no protection against this other disease, any measured vaccine effectiveness would be 103 
indicative of unmeasured confounding. A bias-indicator study of oral cholera vaccine in Mozambique 104 
evaluated the vaccine’s effectiveness against non-cholera diarrhea, and found an effectiveness of 35% 105 
(95% CI -18 to 65%); however after adjustment for known confounders the vaccine effectiveness was 106 
0%. This suggests that while there was confounding of the effectiveness results, it was not due to 107 
unmeasured confounding37.  A limitation of the bias indicator study is the assumption that vaccine 108 
effects are specific to the vaccine target, whereas there is increasing evidence that some vaccines may 109 
have non-specific effects that could reduce the risk for non-targeted infections51. Non-infectious 110 
illnesses (e.g. accidents or injuries) could be considered as outcomes for bias indicators studies. Another 111 
type of study to quantify unmeasured confounding has been dubbed a “sham exposure”50 or “sham 112 
case-control”52 study.    Here vaccine effectiveness of another vaccine is measured against the disease of 113 
interest.  In Kenya, investigators measured the effectiveness of diphtheria-tetanus-pertussis-Hib-114 
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Hepatitis B vaccine against rotavirus disease among children prior to the expected introduction of the 115 
rotavirus vaccine in 2014 and found no protection52. Because sham case-control studies are generally 116 
carried out before the introduction of a new vaccine, they require advance planning and resources. 117 
When feasible, they can be useful for planning case-control studies, for example by revealing the least 118 
biased control group or identifying measurable confounders in the population.   119 
Implementation and adherence to protocols 120 
The quality of data on enrollment, vaccination status, and potential confounders depends on 121 
writing and implementing clear protocols and Standard Operating Procedures (SOPs) for study conduct. 122 
Efforts to recruit cases and controls should be documented using standardized forms such as screening 123 
logs or registers; such documentation can be used to monitor the adherence to study procedures and 124 
identify lapses as quickly as possible.  125 
Because of potential for selection bias in control enrollment for vaccine effectiveness case-126 
control studies, it is particularly important to standardize, document clearly in logs, and regularly 127 
monitor at the field level, the process for enrolling controls.53 This should include the number of 128 
potential controls screened, number and timing of attempts made to enroll potentially eligible controls, 129 
the reasons for non-enrollment of potential controls, the frequency of refusals, and the number and 130 
characteristics of the controls who were not enrolled. Some methods for supervision of field staff 131 
enrolling controls may include GPS tracking of field staff (to monitor their locations and pace of 132 
recruitment and enrollment) and intermittent supervisor monitoring of the homes that were visited. 133 
Any departures from the protocol or SOPs must be reported to study lead investigators and 134 
documented.  135 
Analysis 136 
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The statistical analysis of a case-control study for the evaluation of vaccine effectiveness should 137 
follow directly from the protocol and analysis plan, which should define the outcomes to be examined, 138 
as well as the exposures of interest (e.g. complete schedule, 2 or more doses). The “unadjusted” 139 
effectiveness from a case-control study is calculated as (1 – odds ratio for vaccination) x 100%.  140 
For cases, vaccination status is defined based on the number of doses received before becoming 141 
ill and usually excludes doses received within the two weeks prior to allow for induction of immune 142 
response. For individually matched controls, a reference date should be defined in order to examine the 143 
control’s vaccination status before the corresponding case became ill42; the reference date is often 144 
based on the case’s date of illness onset, but may be based upon the date of hospitalization or sample 145 
collection. Doses received more than two weeks (if this is the period used for the case) before the 146 
reference date should be considered in the analysis. For frequency matched controls, the situation in 147 
which multiple controls are matched to multiple cases, there are different reference dates (or ages) 148 
associated with each of the cases and controls, and the analysis must take account of this. A method for 149 
doing this has been described by Keogh et al54.  150 
The odds ratio is usually calculated from a logistic regression model, using unconditional logistic 151 
regression for unmatched or frequency matched studies, and conditional logistic regression for matched 152 
studies, with strata defined for each matched case-control set 55. For simple conditional logistic 153 
regression, only discordant strata (e.g. vaccinated cases with at least one non-vaccinated control, or 154 
non-vaccinated case with at least one vaccinated control) contribute to the analysis55; thus in settings of 155 
very high or low vaccine coverage, the power of the analyses will be reduced.   156 
While all efforts should be made in the study design phase to minimize confounding (e.g. by 157 
matching), it is usually necessary to also control for confounding in the analysis, where potential 158 
confounders are included as independent variables in a regression model. Because inclusion of multiple 159 
covariates can result in loss of statistical power, it is important to avoid including factors that are not 160 
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true confounders. There is no formal statistical test for evaluating whether to include a potential 161 
confounder in the final analysis46. Some researchers approach the inclusion of confounders based on the 162 
past literature and include all potential confounders in a full model.  Others prefer to evaluate potential 163 
confounders based on the data of the current study.  A common approach to confounder evaluation is 164 
to include both vaccination status and single potential confounders, one at a time, as independent 165 
variables in the logistic regression model.  If the OR associated with vaccination status changes by a 166 
predetermined, albeit arbitrary, percent (e.g. 10%) or more after adjusting for the potential confounder, 167 
then that variable is retained in the final multivariable model since it appears to impact the VE41. 168 
Another approach for determining which variables to include in a multivariable model is the use of 169 
directed acyclic graphs, which are causal diagrams used to identify a subset of covariates that address 170 
confounding while avoiding introduction of bias56. Directed acyclic graphs have been used for case-171 
control vaccine effectiveness studies of influenza57,58.  While different strategies for identifying 172 
important confounding variables are acceptable, the method used should be determined at the stage of 173 
developing the analytic plan.  174 
Before deciding on a final model, some investigators prefer to examine whether the odds ratio 175 
(and thereby the VE) differ between strata of potential confounders (i.e. effect modification). This may 176 
be formally tested using appropriate interaction terms in the regression models. If such interaction is 177 
meaningful and statistically significant, stratum-specific VEs might be reported 59. For example, in a 178 
study of the 7-valent pneumococcal conjugate vaccine in the United States, the effectiveness against 179 
vaccine-type and non-vaccine type invasive pneumococcal disease was presented for healthy children 180 
and those with comorbidities, since this variable was found to have significant interaction with 181 
vaccination status14.  182 
Missing vaccination data present a problem in a vaccine effectiveness case-control study, since 183 
those with missing data likely differ from those with a documented vaccination history in ways that 184 
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could bias effectiveness estimates. One approach to handling missing vaccination histories is to conduct 185 
a sensitivity analysis. The simplest sensitivity analysis assumes those with a missing vaccination history 186 
are either all unvaccinated or all completely vaccinated, providing two estimates of effectiveness under 187 
two different assumptions. A study of the Hib vaccine conducted in the Dominican Republic used this 188 
approach and found very little impact on the results, suggesting that the findings of the primary analysis 189 
were not substantially biased by the missing vaccination history data60. Sensitivity analysis could also be 190 
conducted to examine the impact of low (and potentially biased) enrollment of controls on effectiveness 191 
estimates by assuming a range of vaccine coverage for individuals who were eligible but not enrolled. 192 
Methodological approaches to dealing with missing data have been advancing rapidly, and although 193 
there has been little work in vaccine effectiveness studies evaluating the usefulness of multiple 194 
imputation for missing vaccination histories for enrolled participants (or non-enrolled participants, as 195 
mentioned above), this approach warrants exploration61.  Nonetheless, all possible efforts should be 196 
made to obtain as complete information as possible on vaccination status of cases and controls; no 197 
sensitivity analysis or imputation can fully compensate for data completeness and validity. 198 
Reporting study results 199 
 The STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines 200 
for reporting on case-control studies are an excellent reference for determining the key pieces of 201 
information to record for a vaccine effectiveness study 62. For case-control vaccine effectiveness studies, 202 
it is crucial to provide a clear and explicit description of the recruitment strategy for cases and controls, 203 
and to carefully document non-enrollment as well as enrollment. Readers should be given a clear 204 
understanding of how many potential cases and controls were screened to achieve the number of 205 
enrolled participants and the primary reasons for non-enrollment (e.g. not eligible, unable to contact, 206 
refused participation). The number of cases and controls with no documented vaccination history 207 
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should also be stated in the results. Relevant differences between included and not included cases and 208 
controls, as well as between those with and without reliable vaccination history, should be documented. 209 
 In interpreting the study findings, investigators should focus on the confidence intervals of 210 
effectiveness estimates. Although readers or policy makers may be naturally drawn to point estimates, 211 
confidence intervals add crucial information on the precision of these estimates. Reports of case-control 212 
vaccine effectiveness studies should also include a discussion of the limitations and potential sources of 213 
bias, taking into consideration the inherent limitations of the study design.  214 
Conclusions 215 
The case-control methodology is frequently used to evaluate the effectiveness of new vaccines, 216 
providing important data on the ‘real-world’ performance of vaccines that guide decisions about vaccine 217 
introduction and sustained use63,64. However, the potential for bias and confounding is high, and can 218 
threaten the validity of the findings. Studies aimed at better understanding bias in case-control studies, 219 
such as a simulation model estimating potential biases in influenza vaccine effectiveness studies65, can 220 
advance the field and provide more specific guidance regarding circumstances in which the case-control 221 
approach is likely to yield reliable results.  222 
High quality vaccination data collected using the methods for cases and controls is crucial for 223 
vaccine effectiveness studies; in settings where documented vaccination histories are difficult to obtain, 224 
case-control vaccine effectiveness studies are unlikely to be useful. Variables that confound the 225 
association between vaccination and disease should be carefully measured and adjusted for in the 226 
analysis. In reporting the results of a case-control vaccine effectiveness study, it is important to include 227 
information that provides insight into the degree of possible bias in enrollment and data collection, such 228 
as the number of potential controls screened or the proportion of cases and controls with documented 229 
vaccine history. Vaccine effectiveness estimates should be presented with emphasis on the confidence 230 
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interval rather than the point estimate. In order for case-control studies to accurately guide vaccine 231 
policy decisions, data collection must be thorough and with careful attention to minimize bias, the 232 
analysis performed per the analytic plan with attention to potential confounding, and the results 233 
carefully interpreted and presented.  234 
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